National rollout of Promarker D and Promarker Eso set to begin 26 October
Proteomics International Laboratories Ltd (ASX: PIQ) has scheduled the national rollout of its Promarker D and Promarker Eso blood tests to commence on Monday, 26 October 2026. The rollout will run through Healius Limited (ASX: HLS), its exclusive Australian pathology distribution partner.
It represents the next phase after the controlled market release in Western Australia and the Northern Territory, announced on 14 September 2026. For investors, the tests move from a regional release to nationwide availability through an existing pathology distribution network.
The controlled market release in Western Australia and the Northern Territory was the first revenue-generating launch in the company’s history, and it served as the operational proving ground for the systems now being extended nationally.
When big ASX news breaks, our subscribers know first
What is in place for go-live
Readiness checklist
The company has outlined three elements supporting the 26 October 2026 start:
- Field sales teams have completed training on both tests, including intended clinical uses and access processes.
- Joint sales and marketing plans have been agreed to support clinician education, awareness and appropriate referrals.
- Systems and operational integration will be enabled for go-live, so Healius collection centres are expected to accept patients for blood collection and process payments.
The training is intended to prepare teams to engage with general practitioners and relevant specialists as the rollout commences.
Who does what
Responsibilities are split across the two companies. Proteomics International keeps the testing, while Healius provides reach.
| Role | Proteomics International | Healius |
| Laboratory testing | Performed in its NATA accredited facility | N/A |
| Clinical reporting | Provided by Proteomics International | N/A |
| Scientific and medical support | Provided by Proteomics International | N/A |
| Quality and regulatory compliance | Provided by Proteomics International | N/A |
| Specimen collection | N/A | Supported through its national infrastructure |
| Pathology distribution | N/A | Supported through its national infrastructure |
| Clinician engagement | N/A | Supported through its national infrastructure |
Patient pricing
The tests will initially be available on a private-pay basis at the previously announced Australian patient prices. Promarker D is priced at $495 and Promarker Eso at $997.
Management commentary
Proteomics International CEO and Managing Director David Morris addressed the milestone in the announcement.
David Morris, CEO and Managing Director, Proteomics International
“National rollout is a significant milestone in bringing our Promarker portfolio to Australian clinicians and patients…”
Healius Group Executive – Customer & Commercial, Anthea Muir, focused on the combined capabilities of the two companies.
Anthea Muir, Group Executive – Customer & Commercial, Healius
“This rollout brings together Healius’ national collection network and clinician relationships with Proteomics International’s specialist testing capability, broadening access to the Promarker portfolio…”
How blood-based diagnostic rollouts work
A pathology distribution partnership splits the process into clear steps. A clinician refers a patient, the patient gives blood at a collection centre, a specialist laboratory runs the test, and the clinician receives a report.
Proteomics International describes itself as a Perth-based medical technology company specialising in proteomics, which is the study of proteins and their functions. The company develops precision diagnostic tests and provides specialist bioanalytical services to improve the detection and management of disease.
Clinician awareness and referrals are central to how this model translates into test volumes. That is why the joint sales and marketing plans, aimed at education and appropriate referrals, matter to the commercial case.
Promarker Endo and the commercial outlook
Building toward Promarker Endo
On 13 October 2026, Proteomics International announced it had completed refinement and independent validation of the model underpinning Promarker Endo, its blood test for endometriosis.
The company expects to make the test commercially available during FY27 Q3 (January to March 2027) through the Healius distribution partnership. This is subject to clinical deployment and applicable quality, accreditation and regulatory requirements.
The systems, specimen collection processes and clinician engagement activities established for Promarker D and Promarker Eso are expected to support preparations for that introduction.
For readers wanting the clinical performance numbers behind the endometriosis test, our detailed coverage of the Promarker Endo validation results breaks down the sensitivity and specificity findings across disease stages and the Oxford sample cohort.
Outlook
The announcement outlined the following commercial position:
- The Promarker portfolio remains at an early stage of commercialisation.
- Revenue under the distribution agreement cannot be reliably estimated at this time.
- The company will update the market on material developments in accordance with its continuous disclosure obligations.
The rollout is intended to establish broader access to Promarker D and Promarker Eso through an existing pathology distribution network. Commercial outcomes may depend on factors including implementation timing, clinician adoption, patient utilisation and prevailing market conditions.
Don’t Miss the Next Healthcare Breakout
Join 20,000+ investors receiving FREE breaking ASX healthcare news within minutes of release, complete with in-depth analysis and the full announcement. Click the “Free Alerts” button at Big News Blast to get market-moving updates in your inbox the moment news breaks, ahead of the wider market.